CoChat
Sign Up
Cited by 9Fibromyalgia and Chronic Fatigue Syndrome ResearchPain Mechanisms and TreatmentsMyofascial pain diagnosis and treatment

Elevated Serum MCP-1/CCL2 Levels are Linked with Disease Severity in Patients with Fibromyalgia Syndrome

Open access
Zhao, Yuan-Chuang, Hu, Ting, Chen, Yan, Du, Ke-Tao·2019·Balkan Medical Journal
DOI 10.4274/balkanmedj.galenos.2019.2019.6.47PMC PMC6835162
Open this paper in CoChat — free account

Abstract

Background: Elevated levels of monocyte chemotactic protein-1/chemokine C-C motif ligand 2 have been identified in fibromyalgia patients. Aims: To examine the potential association among serum levels of monocyte chemotactic protein-1/chemokine C-C motif ligand 2 with disease severity of fibromyalgia. Study Design: Cross-sectional study. Methods: Seventy-nine female patients with fibromyalgia and 75 healthy normal controls were included in our study. Serum levels of monocyte chemotactic protein-1/chemokine C-C motif ligand 2 were detected by enzyme-linked immune sorbent assays. The existence of tender points was evaluated based on the standardized manual tender point examination. Pressure pain thresholds at the knees, and bilateral trapezius muscles were measured with an algometer. A visual analog scale and the Revised Fibromyalgia Impact Questionnaire were utilized to assess the degree of pain and functional abilities. Results: Serum levels of monocyte chemotactic protein-1/chemokine C-C motif ligand 2 were significantly greater in patients with fibromyalgia compared with healthy controls (151.6±31.9 pg/mL vs 103.3±25.2 pg/mL, p<0.001). Patients with severe fibromyalgia had significantly higher serum levels of chemokine C-C motif ligand 2 than patients with mild and moderate fibromyalgia (173.1±21.9 pg/mL vs 151.0.0±35.1 pg/mL, p=0.01). Patients with moderate fibromyalgia revealed markedly augmented serum levels of chemokine C-C motif ligand 2 compared with patients with mild fibromyalgia (151.0±35.1 pg/mL vs 133.3±23.9 pg/mL, p=0.03). Serum levels of chemokine C-C motif ligand 2 were positively associated with tender point scores (r=0.455, p<0.001). In addition, serum levels of chemokine C-C motif ligand 2 were positively associated with pressure pain thresholds in both knees and bilateral trapezius muscles (knees: r=-0.349, p=0.002; trapezius muscles: r=-0.318, p=0.004). Finally, we found elevated serum levels of chemokine C-C motif ligand were also positively associated with the visual analog scale (r=0.368, p=0.001), and the Fibromyalgia Impact Questionnaire score (r=0.401, p<0.001). Conclusion: Elevated serum levels of monocyte chemotactic protein-1/chemokine C-C motif ligand 2 are linked to disease severity of fibromyalgia. Therapeutic interventions inhibiting monocyte chemotactic protein-1/chemokine C-C motif ligand 2 in fibromyalgia deserve additional studies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4274/balkanmedj.galenos.2019.2019.6.47

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 29

  1. [2]Talotta R Bazzichi L Di Franco M Casale R Batticciotto A Gerardi MC et al One year in review 2017: fibromyalgia Clin Exp Rheumatol 2017 35 6 12 28681712
  2. [3]Sumpton JE Moulin DE Fibromyalgia Handb Clin Neurol 2014 119 513 27 24365316
  3. [4]Wolfe F Walitt BT Katz RS Häuser W Social security work disability and its predictors in patients with fibromyalgia Arthritis Care Res (Hoboken) 2014 66 1354 63 24515531
  4. [5]Clauw DJ D'Arcy Y Gebke K Semel D Pauer L Jones KD Normalizing fibromyalgia as a chronic illness Postgrad Med 2018 130 9 18 29256764
  5. [6]Coskun Benlidayi I Role of inflammation in the pathogenesis and treatment of fibromyalgia Rheumatol Int 2019 39 781 91 30756137
  6. [7]Wang J Knaut H Chemokine signaling in development and disease Development 2014 141 4199 205 25371357 PMC4302920
  7. [8]Stone MJ Hayward JA Huang C Huma ZE Sanchez J Mechanisms of Regulation of the Chemokine-Receptor Network Int J Mol Sci 2017 8. PMC5343877 28178200
  8. [9]Buck AK Stolzenburg A Hänscheid H Schirbel A Lückerath K Schottelius M et al Chemokine receptor - Directed imaging and therapy Methods 2017 130 63 71 28916148
  9. [10]Cecchinato V Uguccioni M Insight on the regulation of chemokine activities J Leukoc Biol 2018 104 295 300 29668065
  10. [11]Proost P Struyf S Van Damme J Fiten P Ugarte-Berzal E Opdenakker G Chemokine isoforms and processing in inflammation and immunity J Autoimmun 2017 85 45 57 28684129
  11. [12]Deshmane SL Kremlev S Amini S Sawaya BE Monocyte chemoattractant protein-1 (MCP-1): an overview J Interferon Cytokine Res 2009 29 313 26 19441883 PMC2755091
  12. [13]O'Connor T Borsig L Heikenwalder M CCL2-CCR2 Signaling in Disease Pathogenesis Endocr Metab Immune Disord Drug Targets 2015 15 105 18 25772168
  13. [14]Raghu H Lepus CM Wang Q Wong HH Lingampalli N Oliviero F et al CCL2/CCR2, but not CCL5/CCR5, mediates monocyte recruitment, inflammation and cartilage destruction in osteoarthritis Ann Rheum Dis 2017 76 914 22 27965260 PMC5834918
  14. [15]Chizzolini C Brembilla NC Montanari E Truchetet ME Fibrosis and immune dysregulation in systemic sclerosis Autoimmun Rev 2011 10 276 81 20863906
  15. [16]Lin J Kakkar V Lu X Impact of MCP-1 in atherosclerosis Curr Pharm Des 2014 20 4580 8 24862889
  16. [17]Zhang Z Cherryholmes G Mao A Marek C Longmate J Kalos M et al High Plasma Levels of MCP-1 and Eotaxin Provide Evidence for an Immunological Basis of Fibromyalgia Exp Biol Med (Maywood) 2008 233 1171 80 18535166
  17. [18]Alvarez P Green PG Levine JD Role for monocyte chemoattractant protein-1 in the induction of chronic muscle pain in the rat Pain 2014 155 1161 7 24637038 PMC4303347
  18. [19]Wolfe F Smythe HA Yunus MB Bennett RM Bombardier C Goldenberg DL et al The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee Arthritis Rheum 1990 33 160 72 2306288
  19. [20]Graven-Nielsen T Arendt-Nielsen L Assessment of mechanisms in localized and widespread musculoskeletal pain Nat Rev Rheumatol 2010 6 599 606 20664523
  20. [21]Heller GZ Manuguerra M Chow R How to analyze the Visual Analogue Scale: Myths, truths and clinical relevance Scand J Pain 2016 13 67 75 28850536
  21. [22]Salgueiro M Garcia-Leiva JM Ballesteros J Hidalgo J Molina R Calandre EP Validation of a Spanish version of the revised fibromyalgia impact questionnaire (FIQR) Health Qual Life Outcomes 2013 11 132 23915386 PMC3770447
  22. [24]Feinberg T Sambamoorthi U Lilly C Innes KK Potential Mediators between Fibromyalgia and C-Reactive protein: Results from a Large U.S. Community Survey BMC Musculoskelet Disord 2017 18 294 28687081 PMC5501008
  23. [25]Malatji BG Meyer H Mason S Engelke UFH Wevers RA van Reenen M et al A diagnostic biomarker profile for fibromyalgia syndrome based on an NMR metabolomics study of selected patients and controls BMC Neurol 2017 17 88 28490352 PMC5426044
  24. [26]Gur A Oktayoglu P Status of immune mediators in fibromyalgia Curr Pain Headache Rep 2008 12 175 81 18796266
  25. [27]Wallace DJ Linker-Israeli M Hallegua D Silverman S Silver D Weisman MH Cytokines play an aetiopathogenetic role in fibromyalgia: A hypothesis and pilot study Rheumatology (Oxford) 2001 40 743 9 11477278
  26. [28]Gür A Karakoç M Nas K Denli A et al Cytokines and depression in cases with fibromyalgia J Rheumatol 2002 29 358 61 11838856
  27. [29]Littlejohn G Guymer E Neurogenic inflammation in fibromyalgia Semin Immunopathol 2018 40 291 300 29556959
  28. [30]Asberg M Nygren A Leopardi R Rylander G Peterson U Wilczek L et al Novel biochemical markers of psychosocial stress in women PloS One 2009 4 3590 PMC2627901 19177163
  29. [31]White FA Wilson NM Chemokines as pain mediators and modulators Curr Opin Anaesthesiol 2008 21 580 5 18784482 PMC2702665

Cited by

Sorted by citations

Authors
Zhao, Y.-C., Hu, T., Chen, Y., & Du, K.-T.
Affiliations
  • Guangzhou Medical University (CN)
  • Chenzhou First People's Hospital (CN)
Venue
Balkan Medical Journal
Publisher
AVES Publishing Co.
Published
2019-09-05
Volume
36
Issue
6
Pages
331-336
ISSN
  • 1301-3149 (ISSN-L)
  • 2146-3123
  • 2146-3131
DOI
10.4274/balkanmedj.galenos.2019.2019.6.47
PMC
PMC6835162
OpenAlex
W2972017905
Cited by
9
References
1
Citations by year
2026: 2 · 2025: 1 · 2024: 1 · 2022: 2 · 2021: 1 · 2020: 2
FWCI
1.00
Type
journal article
Language
en
Open access
Locations
  • Balkan Medical Journal (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Fibromyalgia and Chronic Fatigue Syndrome Research
  • Health Sciences › Medicine › Physiology › Pain Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Myofascial pain diagnosis and treatment
Keywords
fibromyalgia, MCP-1, chemokines, disease severity, tender points, pressure pain threshold, pain sensitivity, fibromyalgia impact, women, biomarkers, trapezius, knee pain, Revised Fibromyalgia Impact Questionnaire, visual analogue scale, algometry
MeSH terms
Adult, Aged, Analysis of Variance, Cross-Sectional Studies, Female, Fibromyalgia, Humans, Middle Aged, Severity of Illness Index, Biomarkers, Chemokine CCL2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review